Journal: PeerJ

Article Title: Comparative genomics of hospital-associated vancomycin-resistant Enterococcus faecium from regional tertiary hospitals in Thailand

doi: 10.7717/peerj.21354

Figure Lengend Snippet: A maximum-likelihood phylogenetic tree was constructed using a recombination-filtered core SNP alignment generated through Snippy, Snippy-core, and Gubbins, with E. faecium reference genome GCF_009697285.1 . Tree inference was performed using IQ-TREE with ultrafast bootstrap support values shown at internal nodes. The phylogenetic tree was visualized and annotated using iTOL. Two major phylogenetic groups, designated as Clade I and Clade II, were observed. Antimicrobial resistance genes and mutations were identified using thresholds of ≥ 90% sequence identity and ≥ 60% coverage. The heatmap alongside the tree displays the sequence types (STs), presence/absence of antimicrobial resistance genes, and corresponding phenotypic disk diffusion results for each isolate.

Article Snippet: The following antimicrobial disks were included (Oxoid, Basingstoke, UK): ampicillin (AP), ciprofloxacin (CIP), chloramphenicol (C), gentamycin (CN), linezolid (LZD), penicillin (PG), streptomycin (S), teicoplanin (TEC), tetracycline (TE), and vancomycin (VA).

Techniques: Construct, Generated, Sequencing, Diffusion-based Assay

Journal: Heliyon

Article Title: Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides

doi: 10.1016/j.heliyon.2024.e27852

Figure Lengend Snippet: Minimal inhibitory concentrations (MIC) of antimicrobials against E. coli ATCC 25922 at two bacterial concentrations.

Article Snippet: Temporin-L was purchased from CRB Discovery; ampicillin sodium salt and kanamycin sulphate were purchased from Carl Roth; 3,6-bis(dimethylamino)-10-nonyl-acridinium bromide (NAO), gentamicin, penicillin G, levofloxacin, nalidixic acid, and Lisogeny-Broth (LB) medium were purchased from Sigma Aldrich.

Techniques: Sequencing

Journal: Heliyon

Article Title: Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides

doi: 10.1016/j.heliyon.2024.e27852

Figure Lengend Snippet: Minimal inhibitory concentrations (MIC) of antimicrobials against dividing (LB) and non-dividing (PBS) cells of E. coli ATCC 25922. Bacterial cell density – 5 × 10 5 CFU/mL.

Article Snippet: Temporin-L was purchased from CRB Discovery; ampicillin sodium salt and kanamycin sulphate were purchased from Carl Roth; 3,6-bis(dimethylamino)-10-nonyl-acridinium bromide (NAO), gentamicin, penicillin G, levofloxacin, nalidixic acid, and Lisogeny-Broth (LB) medium were purchased from Sigma Aldrich.

Techniques:

Journal: Heliyon

Article Title: Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides

doi: 10.1016/j.heliyon.2024.e27852

Figure Lengend Snippet: Synergistic interactions between peptides and antibiotics against E. coli ATCC 25922 at two bacterial concentrations. MIC A – MIC of peptide alone; MIC B – MIC of antibiotic alone; MIC AB – MIC of peptide in combination with antibiotic; MIC BA – MIC of antibiotic in combination with peptide; FICI – fractional inhibitory concentration index.

Article Snippet: Temporin-L was purchased from CRB Discovery; ampicillin sodium salt and kanamycin sulphate were purchased from Carl Roth; 3,6-bis(dimethylamino)-10-nonyl-acridinium bromide (NAO), gentamicin, penicillin G, levofloxacin, nalidixic acid, and Lisogeny-Broth (LB) medium were purchased from Sigma Aldrich.

Techniques: Concentration Assay

Journal: Heliyon

Article Title: Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides

doi: 10.1016/j.heliyon.2024.e27852

Figure Lengend Snippet: CAMPs induce ROS-independent DSBs in genomic DNA of E. coli ATCC 25922. (A) LMA-encapsulated cells were treated with CAMPs (100 μg/mL), levofloxacin (0.5 μg/mL), or ampicillin (50 μg/mL) (see Materials and Methods section) and DSB formation was monitored using PFGE. Lane 1 – levofloxacin; Lane 2 – ampicillin; Lane 3 – L1L; Lane 4 – L1D; Lane 5–24L; Lane 6–24D; Lane 7 – LCAPL2; Lane 8 – LCAPL8; Lane 9 – untreated cells; (B) LMA-encapsulated cells were treated with peptides 24L, L1D, and ST1 in the absence (lanes 2, 4, and 6) or presence (lanes 3, 5, and 7) of 100 mM TU. Lane 1 and Lane 8 show levofloxacin and untreated cells, respectively. For full images please see Supplemental Material.

Article Snippet: Temporin-L was purchased from CRB Discovery; ampicillin sodium salt and kanamycin sulphate were purchased from Carl Roth; 3,6-bis(dimethylamino)-10-nonyl-acridinium bromide (NAO), gentamicin, penicillin G, levofloxacin, nalidixic acid, and Lisogeny-Broth (LB) medium were purchased from Sigma Aldrich.

Techniques: